Exelixis

The CABINET trial showed cabozantinib significantly improved progression-free survival in previously treated patients with advanced extrapancreatic or pancreatic neuroendocrine tumors compared to placebo. Adverse events were consistent with cabozantinib's known safety profile, supporting its use as a new treatment option.

Cabozantinib significantly improved progression-free survival in advanced pancreatic and extra-pancreatic neuroendocrine tumors, potentially becoming the new standard of care, according to the Phase III CABINET trial results.

Higher fucosylation and sialylation of serum proteins linked to worse outcomes in advanced RCC with nivolumab plus cabozantinib and sunitinib, according to CheckMate-9ER study. Serum glycoproteins involved in complement cascade and lipid metabolism may predict response to nivolumab plus cabozantinib vs sunitinib. Early exploratory work suggests glycosylation could be a focus for further biomarker development in RCC.

The phase 3 CONTACT-02 trial showed cabozantinib and atezolizumab combination favored over a second novel hormonal therapy in metastatic castration-resistant prostate cancer, though OS trend did not achieve statistical significance. Median OS was 14.8 months vs 15.0 months, with subgroup analysis indicating survival advantage for liver and bone metastasis patients. Safety profile consistent with other trials. Exelixis plans FDA submission, while Ipsen opts not to pursue regulatory submissions outside US and Japan.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival in previously treated advanced neuroendocrine tumors, with no new safety concerns. The data was presented at ESMO 2024 and published in the New England Journal of Medicine.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

The CABINET phase III trial showed cabozantinib significantly improved median progression-free survival (PFS) in previously treated neuroendocrine tumors (NETs), with 13.8 months for pNET and 8.4 months for epNET compared to 4.4 and 3.9 months for placebo, respectively. The results, presented at ESMO 2024 and published in NEJM, support cabozantinib as a potential new standard of care for advanced NET patients.

Ipsen’s Phase III CONTACT-02 trial of Cabometyx with Roche’s Tecentriq in mCRPC failed to meet OS improvement at 24 months, leading to no regulatory submissions for the combo therapy. Despite this, Exelixis plans to submit a supplemental new drug application to the FDA for the combo in mCRPC.

The Renal Cell Carcinoma Clinical Trial Pipeline Market is projected to grow significantly from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes. The market is segmented by type and application, with key players including Amgen, AstraZeneca, and Pfizer. Clinical trials focus on novel therapies, drug combinations, and targeted treatments, aiming to improve outcomes for renal cell carcinoma patients.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival (PFS) in previously treated advanced neuroendocrine tumors (pNET and epNET), with PFS of 13.8 months vs 4.4 months for pNET and 8.4 months vs 3.9 months for epNET. The study also demonstrated benefits across all clinical subgroups and a safety profile consistent with previous findings, leading to an early unblinding of the trial and a supplemental new drug application for cabozantinib.